adxs,,,,,,

Advaxis trading higher following positive KEYTRUDA data from MerckFont size: A | A | A
9:59 AM ET 3/24/15 | Briefing.com
Merck this morning announced Phase 3 study (KEYNOTE-006) investigating KEYTRUDA (pembrolizumab) compared to ipilimumab in the first-line treatment of patients with advanced melanoma has met its two primary endpoints of progression-free survival and overall survival. The trial will be stopped early based on the recommendation of the study's independent Data Monitoring Committee.

Advaxis (ADXS) in January said it anticipates commencing with Merck (MRK) patient enrollment for the Phase 1/2 ADXS-PSA/KEYTRUDA (pembrolizumab) combination study in metastatic, castration-resistant prostate cancer (mCRPC) in first quarter 2015.
 

Allegati

  • adxs.png
    adxs.png
    19,4 KB · Visite: 115
tac:
 

Allegati

  • adxs2.png
    adxs2.png
    19,7 KB · Visite: 101
sembra diretta
nuovi max$$$$$

enorme!
 

Allegati

  • adxs.png
    adxs.png
    19,7 KB · Visite: 98
sembra diretta
nuovi max$$$$$

enorme!

con questo titolo avete fatto soldi a palate complimenti???sembra diretto verso i 30...fino a quando c'e il vento favorevole della speculazione ogni target al rialzo e' possibile...in bocca al lupo...
 
con questo titolo avete fatto soldi a palate complimenti???sembra diretto verso i 30...fino a quando c'e il vento favorevole della speculazione ogni target al rialzo e' possibile...in bocca al lupo...

un bel colpo!!!!
grafico pulito
 

Allegati

  • adxs.png
    adxs.png
    19,7 KB · Visite: 86
mmmmmmmmmmmmm


Is ADXS the next JAZZ

Courtesy of bourbon_on_my_cornflakes:

I'm sure this board gets plenty of penny stocks claiming to be the next JAZZ. Here's how ADXS is different. ADXS is not a penny stock anymore, the market cap is $642 million. ADXS has performed spectacularly since last november, going from $3 a share to $23.61, so there is a track record of superb stock performance.

The management team is first rate. The CEO is Dan O"Conner, who as CEO of Imclone sold that company for $6 billion. He stated in February that he thinks ADXS can be worth more. The Chief Medical Officer is Dr. Mauro, who used to be the chief of research at Merck. He joined ADXS after having 6 months to stress test their products in combination with Keytruda, and since joining ADXS has set up the combo with Merck.

The science is first rate, licensed from U Penn, and is in the hot area of immuno-oncology, vaccines that kill cancer. It uses a listeria vector and doesnt require chemo adjuvants.

The stock is clearly massively undervalued RIGHT NOW. A competitor, ADRO, that uses an inferior pirated version of the listeria technology, just IPOed this month and rose to a $2.4 billion market cap. ADXS's market cap is just 1/4 of ADRO's and the market is waking up to this fast. the last 4 days have seen ADRO drop and ADXS rise by roughly similar percentages.

In testing ADXS's vaccines have shown minimal side effects and great effects against various cancers. The combination with Merck's Keytruda will target prostate cancer. If given BTD status, it could be on the market in a year. That would be a huge product. They also have a vaccine which targets HER2 expression, that looks to be highly effective against breast cancer, another huge market. ADXS's vaccines are far cheaper and safer than Car-T treatments like JUNO's, yet JUNO's market cap is over $4 billion and ADXS's is $642 million.

So if you are looking for another JAZZ that has the potential to go from $23 to $189 in a couple years, please look at ADXS. And if you drop bye, say hi
 
extra long$$$$$$$$$$$$$$$$$$$$$$$$$

Advaxis Prices $53 Million Public Offering of Common StockFont size: A | A | A
9:17 AM ET 4/30/15 | GlobeNewswire
Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage cancer immunotherapy company, today announced the pricing of its previously announced underwritten public offering of 2,800,000 shares of its common stock at a public offering price of $19.00 per share. Advaxis has also granted the underwriters a 30-day option to purchase up to an additional 420,000 shares of common stock from Advaxis. The gross proceeds to Advaxis from the public offering are expected to be $53.2 million, before deducting underwriting discounts and commissions and other estimated offering expenses. The offering is expected to close on May 5, 2015, subject to customary closing conditions. Advaxis intends to use the net proceeds from the public offering to fund its continued research and development initiatives in connection with expanding its product pipeline and for other general corporate purposes.

Jefferies LLC and Barclays Capital Inc. are acting as joint book-running managers for the offering, Guggenheim Securities, LLC is acting as lead manager, and Janney Montgomery Scott LLC, Aegis Capital Corp. and H.C. Wainwright & Co., LLC are acting as co-managers.

The securities described above are being offered by Advaxis pursuant to a "shelf" registration statement on Form S-3 (File No. 333-203497) that was declared effective by the Securities and Exchange Commission (SEC) on April 27, 2015. A final prospectus supplement and an accompanying prospectus relating to the offering will be filed with the SEC. Electronic copies of the final prospectus supplement and the accompanying prospectus relating to this offering may be obtained, when available, by contacting Jefferies LLC, 520 Madison Avenue, 2nd Floor, New York, NY, 10022, Attention: Equity Syndicate Prospectus Department, or by telephone at 877-547-6340, or by email at prospectus_department@jefferies.com or Barclays Capital Inc. c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by calling (888) 603-5847 or by emailing Barclaysprospectus@broadridge.com. Investors may also obtain these documents for no charge by visiting the SEC's website at U.S. Securities and Exchange Commission | Homepage.

Before investing in the offering, you should read in their entirety the prospectus supplement and the accompanying prospectus and the other documents that Advaxis has filed with the SEC that are incorporated by reference in the prospectus supplement and the accompanying prospectus, which provide more information about Advaxis and the offering.

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Advaxis, Inc.

Advaxis is a clinical-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary Lm-LLO platform technology. The Lm-LLO technology, using bioengineered live attenuated Listeria monocytogenes bacteria, is the only known cancer immunotherapy agent shown in preclinical studies to both generate cancer fighting T-cells directed against a cancer antigen and neutralize Tregs and myeloid-derived suppressor cells (MDSCs), that protect the tumor microenvironment from immunologic attack and contribute to tumor growth. Advaxis's lead Lm-LLO immunotherapy, ADXS-HPV, targets human papillomavirus (HPV)-associated cancers and is in clinical trials for three indications: Phase 2 in invasive cervical cancer, Phase 1/2 in head and neck cancer, and Phase 1/2 in anal cancer. The FDA has granted Advaxis orphan drug designation for each of these three indications. The Company plans to initiate a registrational clinical program for cervical cancer in 2015 and has established licensing partners in India and Asia for commercialization in those regions. Advaxis entered into a clinical trial collaboration with MedImmune, the global biologics research and development arm of AstraZeneca, for a Phase 1/2 immunotherapy study to evaluate the safety and efficacy of MedImmune's investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with Advaxis's ADXS-HPV as a treatment for patients with advanced, recurrent or refractory HPV-associated cervical cancer and HPV-associated head and neck cancer.

Advaxis's second Lm-LLO immunotherapy candidate in clinical testing will be ADXS-PSA, which is being developed to address prostate cancer. Advaxis entered into a clinical trial collaboration agreement with Merck & Co., Inc. ("Merck"), known as MSD outside the United States and Canada, through its subsidiaries, to evaluate the combination of Advaxis's Lm-LLO cancer immunotherapy, ADXS-PSA, with Merck's PD-1 checkpoint inhibitor KEYTRUDA(R) (pembrolizumab). The ongoing clinical trial is designed to evaluate the safety and efficacy of ADXS-PSA as monotherapy and in combination with pembrolizumab in a Phase 1/2 study of patients with previously treated metastatic, castration-resistant prostate cancer.

Advaxis is also developing Lm-LLO immunotherapy ADXS-HER2, to target the HER2 receptor expressing cancers. HER2 is expressed in certain solid-tumor cancers, including osteosarcoma, breast cancer, esophageal, and gastric cancer. ADXS-HER2 has received orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of osteosarcoma. Advaxis is developing ADXS-HER2 for both human and animal-health, and has seen encouraging data in canine osteosarcoma, which is considered a model for human osteosarcoma. Advaxis has licensed ADXS-HER2 and three other immunotherapy constructs to Aratana Therapeutics, Inc. for pet therapeutics.
 
Indietro